share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  04/29 06:18
Moomoo AI 已提取核心信息
Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.
Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.
生物技术公司Alterity Therapeutics于2024年4月29日在美国2024年世界孤儿药大会上公布了其主要候选药物 ATH434 的新数据。提供的数据表明，ATH434 有可能作为铁伴侣治疗弗里德赖希共济失调，这是一种罕见的神经退行性疾病。与传统的铁螯合剂不同，ATH434 旨在将铁重新分配到体内，而不是将其去除。这可以通过降低不稳定的铁水平和减缓疾病进展来解决弗里德赖希共济失调等疾病的病理问题。这项研究由韦恩州立大学的阿什利·帕尔提出，强调了 ATH434 独特的铁靶向特性，以及与传统螯合剂相比，它对铁的亲和力较低。ATH434 已经完成了 1 期研究，目前正在进行两项多系统萎缩 (MSA) 的 2 期临床试验，MSA 治疗由美国食品药品管理局和欧盟委员会授予孤儿药资格。该公告已获得首席执行官戴维·斯塔姆勒的授权，海报展示可在Alterity的网站上公布。
生物技术公司Alterity Therapeutics于2024年4月29日在美国2024年世界孤儿药大会上公布了其主要候选药物 ATH434 的新数据。提供的数据表明，ATH434 有可能作为铁伴侣治疗弗里德赖希共济失调，这是一种罕见的神经退行性疾病。与传统的铁螯合剂不同，ATH434 旨在将铁重新分配到体内，而不是将其去除。这可以通过降低不稳定的铁水平和减缓疾病进展来解决弗里德赖希共济失调等疾病的病理问题。这项研究由韦恩州立大学的阿什利·帕尔提出，强调了 ATH434 独特的铁靶向特性，以及与传统螯合剂相比，它对铁的亲和力较低。ATH434 已经完成了 1 期研究，目前正在进行两项多系统萎缩 (MSA) 的 2 期临床试验，MSA 治疗由美国食品药品管理局和欧盟委员会授予孤儿药资格。该公告已获得首席执行官戴维·斯塔姆勒的授权，海报展示可在Alterity的网站上公布。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息